与赖诺普利治疗高血压成功相关的基因组标志物：一项初步研究。

Genomic markers associated with successful treatment of hypertension with lisinopril: A pilot study.

出版信息

Int J Clin Pharmacol Ther. 2021 Jul;59(7):506-510. doi: 10.5414/CP203910.

DOI:10.5414/CP203910

PMID:33769277

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8383846/

Abstract

OBJECTIVE

To identify single nucleotide variants (SNVs) associated with lisinopril effectiveness.

MATERIALS AND METHODS

This was an observational study using a candidate gene approach to examine SNVs associated with lisinopril effectiveness. Drug effectiveness was defined as 10% decrease in systolic blood pressure at 1 week follow-up. We used the Illumina GWAS MEGA chip to examine variants in the renin/angiotensin pathway that may be associated with drug effectiveness.

RESULTS

61 subjects were enrolled, and 33 (54.1%) were responsive to lisinopril therapy. SNVs in (p = 0.0141), (p = 0.0192), and (p = 0.0002) were found to be associated with successful treatment on lisinopril. Conclusion and relevance: SNVs in the renin and angiotensin pathway are associated with lisinopril effectiveness in a pilot cohort of patients with uncontrolled hypertension.

摘要

目的

鉴定与赖诺普利疗效相关的单核苷酸变异（SNVs）。

材料和方法

这是一项采用候选基因方法的观察性研究，旨在研究与赖诺普利疗效相关的 SNVs。药物疗效定义为 1 周随访时收缩压降低 10%。我们使用 Illumina GWAS MEGA 芯片检测肾素/血管紧张素途径中可能与药物疗效相关的变异。

结果

共纳入 61 例患者，其中 33 例（54.1%）对赖诺普利治疗有反应。在肾素和血管紧张素途径中的 SNVs （p = 0.0141）、（p = 0.0192）和（p = 0.0002）与赖诺普利治疗成功相关。结论和相关性：在未经控制的高血压患者的试点队列中，肾素和血管紧张素途径中的 SNVs 与赖诺普利的疗效相关。